CN Patent

CN102186465A — 反胺苯环醇与nsaid的共晶

Assigned to Esteven Pharmaceutical Co ltd · Expires 2011-09-14 · 15y expired

What this patent protects

本发明涉及反胺苯环醇和选自NSAID的共晶前体的共晶、其制备方法及其作为药物或在药物制剂中的用途，尤其是用于治疗疼痛的用途。在一种优选实施方式中，该共晶是(-)-反胺苯环醇和(S)-萘普生(1∶2)的共晶；(+)-反胺苯环醇和(R)-萘普生(1∶2)的共晶或(外消旋)-盐酸反胺苯环醇-塞来昔布(1∶1)的共晶。

USPTO Abstract

本发明涉及反胺苯环醇和选自NSAID的共晶前体的共晶、其制备方法及其作为药物或在药物制剂中的用途，尤其是用于治疗疼痛的用途。在一种优选实施方式中，该共晶是(-)-反胺苯环醇和(S)-萘普生(1∶2)的共晶；(+)-反胺苯环醇和(R)-萘普生(1∶2)的共晶或(外消旋)-盐酸反胺苯环醇-塞来昔布(1∶1)的共晶。

Drugs covered by this patent

Patent Metadata

Patent number
CN102186465A
Jurisdiction
CN
Classification
—
Expires
2011-09-14
Drug substance claim
No
Drug product claim
No
Assignee
Esteven Pharmaceutical Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.